Halozyme Q1 Beats Estimates, Guidance Below Consensus

Halozyme posted Q1 adjusted EPS $1.60 beating estimate $1.54 and revenue $377M up 42% YoY, exceeding forecasts.
Royalty revenue rose 43% YoY to $240.7M, driven by ENHANZE partner products DARZALEX SC, VYVGART Hytrulo, and Phesgo.
Full‑year 2026 adjusted EPS guidance $7.75‑$8.25 (midpoint $8.00) fell short of $8.09 consensus, while revenue outlook $1.71‑$1.81B matches expectations.
Halozyme launched a $1 billion share repurchase program, targeting at least $400 million of buybacks in 2026.